What Delcath Systems, Inc. does.

Unless the context otherwise requires, all references in this Annual Report on Form 10-K to the “Company”, “Delcath”, “Delcath Systems”, “we”, “our”, and “us” refers to Delcath Systems, Inc., a Delaware corporation, incorporated in August 1988, and all entities included in our consolidated financial statements. Our corporate offices are located at 566 Queensbury Avenue, Queensbury, New York 12804. Our telephone number is (518) 743-8892 and our internet address is www.delcath.com. The information found on, or otherwise accessible through, our website is not incorporated by reference into, and does not form a part of, this Annual Report on Form 10-K.

We are an interventional oncology company focused on the treatment of cancers primary or metastatic to the liver. Our lead product, the HEPZATO TM KIT (melphalan for Injection/Hepatic Delivery System), a drug/device combination product (“HEPZATO” or “HEPZATO KIT”), was approved by the US Food and Drug Administration (the “FDA”) on August 14, 2023, indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection, or radiation. The first commercial use of the HEPZATO for the treatment of metastatic hepatic dominant uveal melanoma (“mUM”) took place in January 2024.

Revenue and profit, by fiscal year.

More on DCTH.

• Delcath Systems, Inc. summary
• Delcath Systems, Inc. financial statements
• Delcath Systems, Inc. key metrics
• Delcath Systems, Inc. health scores and style box
• Delcath Systems, Inc. earnings
• Delcath Systems, Inc. dividends
• Delcath Systems, Inc. valuation
• Delcath Systems, Inc. ownership and insiders
• Delcath Systems, Inc. peers

Figures from Delcath Systems, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.